|
||
Hemostan Dosage |
||
Applies to the following strength(s): 500 mg; 100 mg/mL; 650 mg
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
For the treatment of cyclic heavy menstrual bleeding:
1,300 mg (two 650 mg tablets) orally three times a day (3,900 mg/day) for a maximum of 5 days during monthly menstruation.
For patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction:
Immediately before dental extraction in patients with hemophilia, administer 10 mg per kg body weight intravenously. Following surgery, a dose of 10 mg per kg body weight intravenously three to four times daily, may be used for 2 to 8 days.
Hemostan has had limited use in pediatric patients, principally in connection with tooth extraction. The limited data suggest that dosing instructions for adults can be used for pediatric patients needing therapy.
For patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction:
Immediately before dental extraction: 10 mg per kg body weight intravenously
Following surgery: 10 mg per kg body weight intravenously three to four times daily, may be used for 2 to 8 days.
Surgery for congenital heart disease (to reduce perioperative blood loss and need for transfusions):
(not FDA approved, limited data available, dose not established, variable dosing regimens reported)
2 months to 15 years:
loading dose: 100 mg/kg intravenously, followed by 10 mg/kg/hour infusion (continued until ICU transport) and 100 mg/kg priming dose when bypass initiated;
or
loading dose: 10 mg/kg intravenously, priming dose: 10 mg/kg and 10 mg/kg after protamine.
Surgery for scoliosis (to reduce perioperative blood loss and need for transfusions):
(not FDA approved, limited data available, dose not established, variable dosing regimens reported)
8 to 18 years:
loading dose: 100 mg/kg intravenously, followed by infusion: 10 mg/kg/hour until skin closure
or
loading dose: 20 mg/kg intravenously, followed by 10 mg/kg/hour infusion
or
loading dose: 10 mg/kg intravenously and 1 mg/kg/hour infusion.
For the treatment of cyclic heavy menstrual bleeding (ages 12 to less than 18):
1,300 mg (two 650 mg tablets) orally three times a day (3,900 mg/day) for a maximum of 5 days during monthly menstruation.
Oral
:
Serum creatinine above 1.4 mg/dL and less than or equal to 2.8 mg/dL:
1300 mg (two 650 mg tablets) orally two times a day for a maximum of 5 days during menstruation.
Serum creatinine above 2.8 mg/dL and less than or equal to 5.7 mg/dL:
1300 mg (two 650 mg tablets) orally once a day for a maximum of 5 days during menstruation.
Serum creatinine above 5.7 mg/dL:
650 mg (one 650 mg tablet) orally once a day for a maximum of 5 days during menstruation.
Intravenous
:
Serum creatinine 1.36 to 2.83 mg/dL:
10 mg/kg intravenously twice a day.
Serum creatinine 2.83 to 5.66 mg/dL:
10 mg/kg intravenously once a day.
Serum creatinine greater than 5.66 mg/dL:
5 mg/kg intravenously every 24 hours.
No dose adjustment is needed in patients with hepatic impairment.
Data not available
Tell your doctor about all other medicines you use, especially:
any type of medication to treat a bleeding episode or a blood clot; or
factor IX (Bebulin VH, Konyne 80, Profilnine SD, Proplex T, and others).
This list is not complete and other drugs may interact with Hemostan. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
Contraindications for Co-Administration: Hemostan should not be co-adminstered with thrombin. Co-administration may cause a thrombosis tendency. It increases the tendency towards thrombosis due to the thrombogenic property of Hemostan.
Precautions for Co-Administration: Hemostan should be administered with care when co-administered with the following drugs.
Hemocoagulase: Co-administration at high doses may cause a thrombosis tendency. Due to the antiplasmin action of Hemostan, fibrin clots formed by hemocoagulase may persist in the blood stream for a relatively long period of time, which may result in a prolonged thrombotic state.
Batroxobin: Co-administration may cause thromboembolism. Hemostan inhibits the decomposition of desA fibrin polymer produced by batroxobin.
Coagulation Factor Agents (Eptacog-α): Coagulation may be further activated at sites with enhanced local fibrinolysis eg, the oral cavity. Coagulation factors exert hemostatic actions by activating the coagulation system, where as Hemostan exerts hemostatic actions by inhibiting the fibrinolytic system.
Users | % | ||
---|---|---|---|
3 times in a day | 14 | 60.9% | |
Once in a day | 4 | 17.4% | |
Twice in a day | 3 | 13.0% | |
4 times in a day | 2 | 8.7% |
Users | % | ||
---|---|---|---|
201-500mg | 8 | 53.3% | |
501mg-1g | 6 | 40.0% | |
101-200mg | 1 | 6.7% |
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|